11:21 AM EDT, 04/17/2024 (MT Newswires) -- NeuroBo Pharmaceuticals ( NRBO ) said Wednesday the first patient has been dosed in part 1 of its two-part early-stage trial of DA-1726 for the treatment of obesity.

The company said part 1 of the study will enroll about 45 participants and part 2 about 36 participants, with dosing of first patient in part 2 trial expected in Q3 of 2024.

NeuroBo said it now expects top-line data readout from part 1 trial in Q3 of 2024.

The shares were up more than 8% in recent trading.